Clarus Biologics, Inc.

Our novel adjuvant will help vaccine manufacturers improve the efficacy of their products with its ability to induce broad and heightened immune responses.

  • Stage Full Product Ready
  • Industry Biotechnology
  • Location Chapel Hill, NC, USA
  • Currency USD
  • Founded September 2019
  • Employees 2
  • Incorporation Type C-corp

Company Summary

Clarus will license its proprietary adjuvant to manufacturers of recombinant, subunit, and other vaccine technologies for use in their products treating various disease categories in global markets. It will also manufacture the adjuvant and supply it to these partners for use in those vaccines during commercial distribution.

Team

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free